WORK Medical Technology WOK

WORK Medical Technology Group LTD is a medical device company that concentrates on the research development manufacturing and sale of medical devices. The firm operates primarily through its PRC subsidiaries which design and produce Class I and II products such as endotracheal tubes laryngeal mask airways heat and moisture exchanging filters disposable breathing circuits nebulizer kits and yankauer suction sets. The company also engages in the development of diagnostic equipment like the AI Automated Human Blood Cell Morphology Analyzer. Its headquarters are located in Hangzhou China.

The company generates revenue by manufacturing and selling medical devices under its own brand or through OEM arrangements. Sales are made to domestic customers in China and to overseas markets through a network of distributors. For the fiscal year ended September 30 2025 total revenue was nine million eight hundred forty eight thousand seven hundred fifteen dollars of which eight million two hundred thirty six thousand eight hundred fifty eight dollars came from domestic sales representing eighty four percent and one million six hundred eleven thousand eight hundred fifty seven dollars came from international sales representing sixteen percent. Revenue is derived from a range of products including artery compression tourniquets disposable breathing circuits laryngeal mask airways endotracheal tubes and face masks. The firm also earns income from distribution agreements such as the exclusive rights granted to Shanghai Benke Medical Technology Co Ltd for the AI Automated Human Blood Cell Morphology Analyzer in East China.

The company holds a niche position in the Chinese medical device market where it competes with larger firms such as Henan Tuoren Medical Device Co Ltd Guangzhou Weili Medical Device Co Ltd and Zhejiang Sujia Medical Device Co Ltd. Its competitive advantages stem from a deep understanding of customer needs derived from the founder’s long experience in hospitals and the medical device sector. The firm benefits from cost effective production after upgrading its mask manufacturing lines which increased daily output and lowered costs. It also offers customized and multifunctional masks that meet specific user requirements such as tight fit designs that reduce fogging on glasses. A broad distribution network with over one thousand domestic distributors and dozens of overseas partners enables the company to reach thirty four provinces in China and more than thirty countries across Asia Africa Europe North America South America and Oceania. Additional strengths include ISO 13485 certification CE marking for many products and FDA registration for seventeen items which support entry into regulated markets.

The company serves a diverse customer base that includes hospitals pharmacies and other medical institutions as direct end user customers. It also relies on a large base of domestic distributor customers who resell its products throughout China and on export distributor customers who place its goods in overseas markets. As of the fiscal year ended September 30 2025 the firm had approximately twenty direct end user customers one thousand twenty six domestic distributor customers and fifty seven export distributor customers. While the specific names of the largest customers are not disclosed the firm reports that its top three customers accounted for seven percent five percent and four percent of revenue respectively in the most recent fiscal year. The company’s products are sold through both its own sales team and its extensive distribution network which covers thirty four provincial level administrative regions in China and reaches countries such as Poland Saudi Arabia Germany Brazil Peru South Korea Colombia United Arab Emirates Costa Rica Turkey and many others.